Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress - The ASPIRE-AF trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509142-35-00

Acronym

2019-ASPIREAF

Enrollment

935

Registered

2024-01-29

Start date

2024-01-29

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation after stress (e.g., noncardiac surgery or acute medical illness)

Brief summary

Individual components of the co-primary outcomes, All stroke, All-cause mortality

Interventions

DRUGDABIGATRAN

DRUGEDOXABAN

DRUGRIVAROXABAN

DRUGAPIXABAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Individual components of the co-primary outcomes, All stroke, All-cause mortality	—

Countries

Belgium, Denmark, Finland, Germany, Greece, Italy, Netherlands, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026